Prostate cancer is among the cancer types associated with the accumulation over time of the changes occurring in the genetic structure of the cells forming the prostate gland. These cellular changes can create a picture that can affect the structural integrity of the prostate tissue and, due to the anatomical relationships with neighbouring tissues, may require the assessment of certain findings related to the urinary tract.
The prostate gland is an important organ responsible for secretion production in the male reproductive system and surrounds the initial part of the urethra. Because of this anatomical proximity, the changes occurring in the prostate tissue may make it necessary to carry out clinical assessments related to urine flow, bladder emptying and lower urinary system functions.
Prostate cancer is not addressed as a single type of disease. Characteristics such as the microscopic structure of the cells, their multiplication speed and their distribution within the prostate lead to the disease being divided into different subtypes. These differences form the basis of the medical assessments carried out under headings such as prostate cancer stages, prostate cancer symptoms and prostate cancer treatment methods.
In clinical practice, assessments regarding the course of the disease are made through the joint addressing of scientific criteria such as laboratory data, imaging findings and pathological examinations. For this reason, the prostate cancer diagnosis and monitoring processes are carried out within the framework of an individual clinical approach shaped in line with the individual’s own medical data.
Where Does Prostate Cancer Occur ?
Prostate cancer develops from the cells within the prostate gland, which is located below the bladder in men and surrounds the beginning of the urethra. The prostate gland has a complex structure consisting of secretory glands and the connective tissue supporting these glands. Each of these tissues can carry different cellular characteristics at the microscopic level, and this lays the ground for the cellular changes that can arise in the prostate tissue being classified into various subtypes.
The prostate gland has different anatomical sections called the peripheral zone, the central zone and the transitional zone. The formation of prostate cancer is mostly associated with cellular changes detected in the peripheral zone. This location characteristic may lead to the disease not creating noticeable urinary tract complaints in the early stages in some individuals, and increases the importance of imaging methods in clinical assessments.
Because of the prostate’s close anatomical relationship with the urinary tract and the bladder, the growth or cellular changes developing in the gland tissue may make it necessary to carry out medical assessments related to lower urinary system functions. The location of the disease within the prostate is among the basic elements taken into account in the imaging examinations carried out within the scope of the prostate cancer diagnosis process.
How Common Is Prostate Cancer? In Whom Is It Seen More Frequently?
Prostate cancer is among the most frequently reported cancer types in men worldwide, and its incidence can vary from society to society. These differences are associated with numerous variables such as the population structure of countries, the average lifespan, the level of access to health services and the prevalence of screening practices. While prostate cancer is reported more frequently in some societies, lower rates can be reported in some regions.
Epidemiological assessments show that the likelihood of prostate cancer increases with advancing age. It is accepted that the cellular changes occurring in the prostate tissue are observed more frequently particularly in middle age and older age groups. However, prostate cancer cases can also rarely be reported in younger age groups.
A family history is one of the elements taken into account in individual risk assessments for prostate cancer. The presence of a prostate cancer history in first-degree relatives is among the factors taken into consideration in clinical assessments. In addition, the genetic structure, hormone levels and the biological characteristics of the prostate gland are also among the variables that can be addressed in the assessment process.
In some individuals, lifestyle, dietary habits, the level of physical activity and accompanying metabolic conditions can also be taken into account in clinical assessments related to prostate health. However, the presence of these factors does not mean that prostate cancer will necessarily develop in every individual. Prostate cancer risk is an individual medical topic addressed through the joint assessment of numerous factors and is interpreted with individual clinical data rather than definitive judgements.
What Are the Symptoms of Prostate Cancer ?
Prostate cancer symptoms can arise in different ways depending on the location of the cellular changes in the prostate gland, the volumetric structure of the gland and its anatomical relationship with the urinary tract. In some individuals, noticeable complaints may not be seen in the early stages, and this may lead to the changes in the prostate tissue being noticed over time.
Some prostate cancer symptoms that can be reported in medical assessments are as follows.
- A weakening in urine flow or a feeling of intermittent urination
- Difficulty starting urination and a prolonging of the urination time
- A frequent need to urinate, particularly during the daytime
- An increase in the number of times of getting up to urinate at night
- A feeling of not being able to empty the urine completely and a feeling of fullness in the bladder
- Dribbling after urinating
- Changes such as a colour change in the urine or semen
- Complaints described as a feeling of fullness in the groin or pelvic region
Since these findings can also be seen in benign prostate enlargement and other prostate diseases, they are not diagnostic of prostate cancer on their own. The presence of complaints associated with the prostate is accepted as a situation that needs to be addressed within medical assessment processes.
What Is PSA? Its Relationship With Prostate Cancer
PSA (Prostate-Specific Antigen) is a biochemical protein secreted by the cells located in the prostate gland and measurable in the blood circulation. In clinical practice, the PSA test is used as a laboratory assessment tool that provides indirect information regarding the structural and cellular condition of the prostate tissue.
PSA levels can vary depending on the physiological characteristics of the prostate gland and various changes occurring in the prostate tissue. An increase in prostate volume, inflammatory processes developing in the tissue and benign structural changes are among the situations in which an increase in PSA levels can be observed. In addition, some medical interventions or recent urinary tract infections are also counted among the factors that can affect PSA measurement results.
The relationship between prostate cancer and PSA is defined as PSA being addressed as part of the prostate cancer assessment process rather than being used as a diagnostic test on its own. The PSA result is evaluated together with physical examination findings, imaging methods and, where deemed necessary, pathological examinations. This approach reflects a medical assessment framework aimed at addressing the cellular changes in the prostate tissue in a multifaceted manner.
What Are the Types of Prostate Cancer ?
The types of prostate cancer are defined through pathological classifications made on the basis of the microscopic structures of the cells forming the prostate tissue and their arrangement characteristics within the tissue. This classification is a scientific approach that reveals that prostate cancer is not a single type of disease and consists of subgroups with different biological behaviour characteristics.
The most frequently reported adenocarcinoma is a subtype that can develop from the cells of the prostate gland responsible for secretion production. This subtype covers an important portion of the cellular changes observed in the prostate tissue. In addition, ductal-type tumours, cellular formations that can show neuroendocrine characteristics and some more rarely reported different histological subtypes can also be defined in pathology reports.
These different prostate cancer subtypes can be distinguished from one another in terms of the multiplication speed of the cells, their distribution within the tissue and their microscopic appearance. Subtype information is accepted as scientific data that contributes to the definition of the cellular characteristics of the disease and can be used as a reference in structuring clinical monitoring processes.
Is Every Prostate Cancer the Same?
Not every prostate cancer is the same. The cellular changes arising in the prostate tissue can show different biological behaviours from one another in terms of microscopic structure, multiplication tendency and distribution characteristics within the tissue. This leads to prostate cancer being evaluated not as a single type of disease, but as a spectrum of diseases consisting of different subgroups.
While in some cases the cellular multiplication speed can proceed more slowly, in some cases characteristics that may require close clinical monitoring can be detected. These differences are among the important parameters taken into account in assessments regarding the course of the disease. The change in PSA levels over time, the findings obtained from imaging methods and biopsy/pathology reports are among the medical data that contribute to the understanding of these biological differences.
For this reason, prostate cancer assessment is addressed in line with the individual’s own clinical findings and pathological characteristics rather than a single type of approach. Each individual’s clinical picture is evaluated in the light of individual medical data, and the monitoring processes are structured accordingly.
The Stages of Prostate Cancer
The stages of prostate cancer are scientific classification systems used to describe the location of the disease within the prostate tissue and its distribution throughout the body. Staging aims to reveal within which anatomical boundaries the cellular changes detected in the prostate gland remain and their relationship with surrounding tissues.
In the staging process, the formations remaining limited within the prostate capsule and the findings of extension beyond the capsule are evaluated in detail. In addition, signs of transition to neighbouring organ tissues, the presence of involvement in the lymph nodes and whether there is spread to distant organs are examined in line with the findings obtained from clinical and imaging methods.
The prostate cancer stage information created as a result of these assessments is used as a standard medical reference describing the current spread level of the disease. Staging provides a basic framework in structuring clinical monitoring plans and in keeping medical records in a common language.
How Is Prostate Cancer Diagnosed ?
The diagnosis of prostate cancer covers a multi-step medical process aimed at evaluating the structural and cellular changes detected in the prostate tissue with scientific methods. The aim in this process is to reveal the nature and spread characteristics of the findings in the prostate gland.
In the first assessment stage, the individual’s medical history, lifestyle habits and current complaints are addressed in detail. This information is guiding in the planning of the subsequent examination steps. A digital rectal examination is one of the physical examination methods that can provide clinical information about the surface structure of the prostate gland and possible areas of firmness.
In the laboratory stage, the PSA measurement is evaluated as a parameter that provides indirect data about the cellular condition of the prostate tissue. The PSA results are addressed together with individual characteristics such as age and prostate volume. In situations deemed necessary, ultrasonography and particularly multiparametric prostate MR can be used to evaluate the location and structural characteristics of the foci within the prostate in detail.
To clarify the imaging and laboratory findings, a prostate biopsy is carried out in some cases. The pathological examination carried out on the tissue samples taken reveals the microscopic characteristics of the cells and is accepted as one of the basic references in the scientific confirmation of the prostate cancer diagnosis.
What Does a High PSA Mean?
A high PSA is a laboratory finding expressing the situation in which the PSA level measured in the blood is detected above the range expected according to the individual’s age and the structural characteristics of the prostate gland. This finding may suggest that there could be some changes at the structural or cellular level in the prostate tissue; however, it does not mean a disease definition on its own.
An increase in PSA levels is not only associated with prostate cancer, but can also be observed temporarily in benign prostate enlargement, inflammatory processes developing in the prostate gland, recent urinary tract infections or after some medical interventions. In addition, prostate volume and individual metabolic characteristics are among the factors that can affect PSA results.
For this reason, a high PSA is not evaluated as a diagnostic finding on its own. In clinical practice, the PSA result is interpreted as part of the prostate cancer assessment process by being addressed together with physical examination, imaging methods and, in situations deemed necessary, pathological examinations.
At What PSA Level Does the Risk Increase?
The question “at what PSA level does the risk increase?” is a topic that frequently comes up in the assessment of prostate health; however, answering this question with a single numerical value is not accepted as appropriate from a medical standpoint. PSA levels can show natural differences according to the individual’s age, the volume of the prostate gland and the biological characteristics of the prostate tissue.
In clinical assessments, the PSA result is addressed not only with the measured value itself, but together with the tendency of change over time. The rate of increase that PSA shows over a certain period is among the data that contributes to the assessment of the cellular changes occurring in the prostate tissue. Within this scope, additional criteria such as PSA kinetics and PSA density can be used in some clinical monitoring processes.
For this reason, prostate cancer risk assessment is not made based on a single PSA result. The PSA measurement is interpreted as part of a multifaceted medical assessment process addressed together with examination findings, imaging results and, in situations deemed necessary, pathological examination data.
What Is the Gleason Score?
The Gleason score is a pathological classification system determined as a result of the microscopic-level examination of the tissue samples obtained from a prostate biopsy, describing the architectural arrangement of the cells and their distribution characteristics within the tissue. This score provides a scientific framework regarding the degree of cellular changes observed in the prostate tissue.
In the pathology assessment, a scoring is made by taking into account the extent to which the cells show similarity to normal prostate tissue and their arrangement within the tissue. The Gleason score is the numerical expression of this scoring created based on the microscopic appearance of the cells and is included as a standard reference in pathology reports.
In current reporting practices, the Grade Group classification can also be used together with the Gleason score. This classification aims to define the degree of cellular change within a simpler grouping system. The Gleason and Grade Group information is among the scientific data that contributes to the definition of the cellular characteristics of prostate cancer and is evaluated together by physicians in structuring clinical monitoring plans.
Prostate Cancer Treatment Methods
Prostate cancer treatment methods refer to the medical approaches planned by addressing together the spread status of the cellular changes detected in the prostate tissue, the pathological assessment results and the individual’s general health profile. The aim in this process is the monitoring of the current clinical picture of the disease in line with scientific criteria.
The surgical methods used in clinical practice include the medical interventions covering the surgical removal of the whole or certain parts of the prostate gland. These approaches can be carried out with different techniques according to the location and spread characteristics of the formation within the prostate.
Radiation-based methods are medical approaches in which radiation energy applied at certain doses and areas is used. In these methods, the aim is to create a controlled effect on the targeted area in the prostate tissue, and the application plans are prepared together with imaging data.
Drug-based applications cover the medical approaches in which hormonal regulatory drugs and other systemic drugs are used. These applications are structured by targeting effects at the cellular level and are evaluated within the scope of clinical monitoring processes.
In some individuals, monitoring strategies such as active surveillance or close follow-up can be preferred in line with the biological characteristics of the disease and clinical data. These approaches are medical plans covering the monitoring of the course of the disease through regular check-ups and laboratory/imaging assessments.
Prostate cancer treatment planning is created as a result of a multifaceted clinical assessment process structured in line with the individual’s own medical data.
Prostate Cancer Lifespan and Course
Prostate cancer lifespan and course is a medical concept addressed through the joint assessment of numerous clinical variables such as the biological characteristics of the cellular changes in the prostate tissue and the spread level of the disease. Since the biological structure of each individual’s prostate tissue and general health profile can differ, the course of the disease can also display an appearance that can vary from person to person.
In this process, factors such as the prostate cancer stage, the pathological examination results, the Gleason score, the change in PSA values over time and accompanying chronic health conditions are taken into account in clinical assessments. In addition, data regarding the individual’s age, general immune response and compliance with the monitoring processes are also among the elements that can be addressed in assessments regarding the course of the disease.
For this reason, generalising statements or explanations containing a personal outcome promise regarding lifespan are not part of the medical information approach. In clinical practice, the course of prostate cancer is evaluated in line with the individual’s own medical data, and the clinical monitoring plans are structured according to this individual picture.
Protection From Prostate Cancer and Early Diagnosis
Protection from prostate cancer refers to the preventive health approaches aimed at supporting the long-term health of the prostate tissue. Healthy habits adopted in daily life can contribute to reducing the level of the prostate gland’s exposure to adverse environmental factors and harmful substances. Behaviours such as a balanced diet, regular physical activity, adequate sleep and staying away from harmful habits are among the practices that support prostate health within the framework of general health.
Reducing environmental exposures covers taking protective measures particularly in environments where there is exposure to long-term chemical substances, intense air pollution or some occupational factors. In addition, the individual’s ability to notice the changes occurring in their own body is important in terms of raising awareness about prostate health.
Early diagnosis describes the medical assessment processes aimed at detecting the cellular and structural changes that may occur in the prostate gland at earlier stages. In this process, regular health check-ups, PSA measurements and imaging examinations carried out in situations deemed necessary allow the monitoring of the prostate tissue. Early diagnosis approaches are addressed as part of the clinical assessments structured in line with the individual’s personal risk profile and are accepted as an important element that contributes to raising the level of awareness about prostate health across society.
When Should the PSA Test Be Started?
The time to start the PSA test refers to an individual planning process for the assessment of prostate health and cannot be limited to a single age range. In this process, numerous variables such as the individual’s age, family history, general health condition and lifestyle are addressed together.
In some individuals, the presence of a family history of prostate cancer or certain genetic characteristics may lead to the PSA screening approach coming up at earlier ages. In other individuals, an assessment in line with the age-related changes developing in the prostate tissue can be preferred. For this reason, the decision to start PSA screening is structured on the basis of the personal risk profile rather than general recommendations.
National and international clinical guidelines may recommend different age ranges and application frequencies in terms of PSA screening strategies. Because of these differences, the determination of the suitable approach for the individual is made through a physician’s assessment, and the screening plan is created in line with the individual’s own medical data.
Clinical Monitoring and Assessment Processes
In individuals with a prostate cancer diagnosis, the clinical monitoring and assessment processes refer to the professional health practices covering the regular review of the current condition of the disease and the systematic recording of medical data. The aim in this process is to monitor the course over time of the cellular changes detected in the prostate tissue in the light of scientific data.
Within the scope of monitoring, the laboratory results, imaging examinations and pathology reports are evaluated together. The change in PSA levels over time, possible differences in imaging findings and clinical examination results are among the main data that contributes to the creation of the medical picture regarding the course of the disease. This holistic approach allows clinical monitoring plans to be structured according to the individual’s prostate cancer stage, pathological characteristics and general health profile.
Within this framework, clinical assessment, monitoring and, in situations deemed necessary, medical opinion sharing services for prostate cancer are provided by Oncology Specialist Dr. Hasan Morcalı. Individual monitoring plans are created through the addressing of the individual’s own medical data within the scope of a physician–patient consultation.
Individuals who would like to get information about the clinical monitoring and assessment processes associated with prostate cancer can obtain detailed information regarding the appointment and information processes by getting in touch with the clinic of Dr. Hasan Morcalı.
Frequently Asked Questions About Prostate Cancer
Is prostate cancer seen only at older ages? Prostate cancer is reported more frequently in older age groups; however, it is a disease group that can also rarely be detected in younger age groups. The likelihood of occurrence can increase with age.
Does prostate cancer give symptoms at an early stage? In some individuals, there may not be a noticeable complaint in the early stages. The changes occurring in the prostate tissue can be noticed over time through different clinical findings.
Does the PSA test provide a diagnosis on its own? The PSA test is a laboratory assessment tool that provides indirect information regarding the condition of the prostate tissue. It is not accepted as diagnostic on its own and is addressed together with other medical assessments.
Does every high PSA mean prostate cancer? No. An increase in PSA levels can also be associated with benign prostate enlargement, inflammatory processes or some temporary conditions. A high PSA is interpreted within the clinical assessment.
Why is a prostate biopsy performed? A prostate biopsy allows the microscopic-level examination of the samples taken from the prostate tissue. This examination is a pathological assessment that contributes to the determination of the cellular characteristics.
Is a single treatment method applied in prostate cancer? The medical approaches followed in prostate cancer are planned in line with the stage of the disease, its cellular characteristics and the individual’s general health condition. For this reason, different methods can be evaluated on their own or together.
Why is early diagnosis important? Early diagnosis refers to the medical assessment processes aimed at noticing the changes in the prostate gland at earlier stages and is important in terms of clinical monitoring.
What can be done to support prostate health? Within the general health approach, a balanced diet, regular physical activity and the adoption of healthy lifestyle habits are evaluated among the preventive practices that support prostate health.
The information on this site is not intended for diagnosis or treatment. Please consult your physician for your health problems.
